Non-alcoholic fatty liver and advanced fibrosis in the elderly: Results from a community-based Polish survey
- PMID: 28489307
- DOI: 10.1111/liv.13471
Non-alcoholic fatty liver and advanced fibrosis in the elderly: Results from a community-based Polish survey
Abstract
Background & aims: Development of non-alcoholic fatty liver (NAFL) is dependent on metabolic factors occurring at an increased frequency with advancing age. Until now, few studies have explored the prevalence of NAFL in aged populations. Our study aimed to determine the prevalence of NAFL and advanced fibrosis in the elderly population participating in a national survey of a community-based elderly cohort.
Methods: A total of 3003 participants (mean age 79.6 years, 46.8% male) were enrolled in the study, after applying the following exclusion criteria: individuals younger than 65 years old (n=829) and those with positive serological biomarkers of HBV or HCV infection (n=391), chronic alcohol ingestion (n=727) or incomplete data records (n=745). Based on the fatty liver index (FLI), the participants were classified into three categories: FLI<30 (no NAFL), 30≤FLI<60 (borderline) and FLI≥60 (NAFL). According to the non-alcoholic fatty liver disease (NAFLD) fibrosis score (NFS), the participants were divided into three advanced fibrosis risk categories: NFS<-1.455 (low risk), -1.455≤NFS≤0.676 (intermediate risk) and NFS>0.676 (high risk).
Results: The prevalence of NAFL in the general population was 37.2%; the prevalence reached 51.4% in participants 65-70 years of age and decreased with advancing age (P<.0001). The prevalence of advanced fibrosis was 7.79% (14.8% in the NAFL population) and increased with advancing age (P<.005).
Conclusions: The prevalence of NAFL and metabolically driven advanced fibrosis are relatively common in the elderly population, and these hepatic conditions run in adverse directions with advancing age.
Keywords: advanced fibrosis; diabetes mellitus; elderly; non-alcoholic fatty liver.
© 2017 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
Similar articles
-
Prevalence of Nonalcoholic Steatohepatitis-Associated Cirrhosis in the United States: An Analysis of National Health and Nutrition Examination Survey Data.Am J Gastroenterol. 2017 Apr;112(4):581-587. doi: 10.1038/ajg.2017.5. Epub 2017 Feb 14. Am J Gastroenterol. 2017. PMID: 28195177
-
Non-invasive fibrosis scoring systems can predict future metabolic complications and overall mortality in non-alcoholic fatty liver disease (NAFLD).Scand J Gastroenterol. 2019 Mar;54(3):328-334. doi: 10.1080/00365521.2019.1583366. Epub 2019 Mar 23. Scand J Gastroenterol. 2019. PMID: 30907181
-
Noninvasive fibrosis markers and chronic kidney disease among adults with nonalcoholic fatty liver in USA.Eur J Gastroenterol Hepatol. 2018 Apr;30(4):404-410. doi: 10.1097/MEG.0000000000001045. Eur J Gastroenterol Hepatol. 2018. PMID: 29215435
-
Liver fibrosis in non-alcoholic fatty liver disease - diagnostic challenge with prognostic significance.World J Gastroenterol. 2015 Oct 21;21(39):11077-87. doi: 10.3748/wjg.v21.i39.11077. World J Gastroenterol. 2015. PMID: 26494963 Free PMC article. Review.
-
The association of non-alcoholic fatty liver disease and atrial fibrillation: a review.Ann Med. 2018 Aug;50(5):371-380. doi: 10.1080/07853890.2018.1492147. Epub 2018 Jul 24. Ann Med. 2018. PMID: 29929399 Review.
Cited by
-
Identified in blood diet-related methylation changes stratify liver biopsies of NAFLD patients according to fibrosis grade.Clin Epigenetics. 2022 Nov 30;14(1):157. doi: 10.1186/s13148-022-01377-6. Clin Epigenetics. 2022. PMID: 36447285 Free PMC article.
-
The burden of non-alcoholic steatohepatitis (NASH) among patients from Europe: A real-world patient-reported outcomes study.JHEP Rep. 2019 Jun 15;1(3):154-161. doi: 10.1016/j.jhepr.2019.05.009. eCollection 2019 Sep. JHEP Rep. 2019. PMID: 32039365 Free PMC article.
-
Engineered fibroblast growth factor 19 protects from acetaminophen-induced liver injury and stimulates aged liver regeneration in mice.Cell Death Dis. 2017 Oct 5;8(10):e3083. doi: 10.1038/cddis.2017.480. Cell Death Dis. 2017. PMID: 28981086 Free PMC article.
-
Non-invasive diagnosis of steatosis, inflammatory changes and liver fibrosis in patients with non-alcoholic fatty liver diseases. Pilot study.Arch Med Sci Atheroscler Dis. 2018 Dec 28;3:e179-e183. doi: 10.5114/amsad.2018.81184. eCollection 2018. Arch Med Sci Atheroscler Dis. 2018. PMID: 30775610 Free PMC article.
-
Association between liver fibrosis scores and cardiovascular disease in elderly based on NHANES 1999-2018.Sci Rep. 2025 Jul 2;15(1):23334. doi: 10.1038/s41598-025-06871-4. Sci Rep. 2025. PMID: 40604053 Free PMC article.
Publication types
MeSH terms
Substances
Associated data
- Actions
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical